Diagnosis and management of juvenile idiopathic arthritis

BMJ

Volumn 342, Issue 7788, 2011, Pages 95-102

  Prince, Femke H M ^a,b   Otten, Marieke H ^a   Van Suijlekom Smit, Lisette W A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CELECOXIB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; METOJECT; NAPROXEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ALOPECIA; ANOREXIA; BONE MARROW SUPPRESSION; CALCIUM DEPLETION; CLINICAL FEATURE; CLINICAL PRACTICE; COHORT ANALYSIS; DIFFERENTIAL DIAGNOSIS; GASTROINTESTINAL SYMPTOM; GENETIC SUSCEPTIBILITY; GINGIVITIS; HEADACHE; HIRSUTISM; HUMAN; HYPERTENSION; JUVENILE DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MAGNESIUM DEPLETION; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); VISUAL ANALOG SCALE; VOMITING;

EID: 78651408953     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6434     Document Type: Review

References (32)

1. Ostlie IL, Aasland A, Johansson I, Flato B, Moller A. A longitudinal follow-up study of physical and psychosocial health in young adults with chronic childhood arthritis. Clin Exp Rheumatol 2009;27:1039-46.
2. Davies K, Cleary G, Foster H, Hutchinson E, Baildam E. BSPAR standards of care for children and young people with juvenile idiopathic arthritis. Rheumatol (Oxford) 2010;49:1406-8.
3. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
4. Prakken BJ, Albani S. Using biology of disease to understand and guide therapy of JIA. Best Pract Res Clin Rheumatol 2009;23:599-608.
5. Berkun Y, Padeh S. Environmental factors and the geoepidemiology of juvenile idiopathic arthritis. Autoimmun Rev 2010;9:A319-24.
6. Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007;56:1974-84.
7. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2006;20:279-300.
8. Davidson J. Juvenile idiopathic arthritis: a clinical overview. Eur J Radiol 2000;33:128-35.
9. Australian Government. Clinical guideline for the diagnosis and management of juvenile idiopathic arthritis. www.racgp.org.au/Content/ NavigationMenu/ClinicalResources/RACGPGuidelines/Juvenileidiopathicarthritis/ RACGP-JIA-guideline.pdf.
10. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 2003;14:395-8.
11. Albers HM, Wessels JA, van der Straaten RJ, Brinkman DM, Suijlekom-Smit LW, Kamphuis SS, et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum 2009;61:46-51.
12. Van Rossum MA, van Soesbergen RM, Boers M, Zwinderman AH, Fiselier TJ, Franssen MJ, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 2007;66:1518-24.
13. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
14. Sherry DD, Stein LD, Reed AM, Schanberg LE, Kredich DW. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 1999;42:2330-4.
15. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006;2:28-34.
16. Minden K. Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 2009;72(suppl 1):20-5.
17. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, Van Rossum MA, Hopppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:138-42.
18. Ringold S, Wallace CA, Rivara FP. Health-related quality of life, physical function, fatigue, and disease activity in children with established polyarticular juvenile idiopathic arthritis. J Rheumatol 2009;36:1330-6.
19. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
20. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research A, Pediatric Rheumatology International Trials O, Pediatric Rheumatology Collaborative Study G. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
21. Hull RG. Management guidelines for arthritis in children. Rheumatol (Oxford) 2001;40:1308.
22. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84.
23. Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatol (Oxford) 2004;43:1288-91.
24. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849-57.
25. Van Rossum MA, Fiselier TJ, Franssen MJ, Zwinderman AH, ten Cate R, van Suijlekom-Smit LW, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16.
26. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK, Lahdenne P, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66.
27. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
28. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
29. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
30. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis Rheum 2010 online 4 November.
31. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010;6:561-71.
32. Shenoi S, Wallace CA. Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep 2010;12:80-6.